GlassScriptPhysician profile
Cory Foster
NPI 1083950935
$4,763.79
in general payments reported to CMS, 2019-2025
36 companies · $759 in 2025
The $759 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $913 · 2023: $1,512 · 2024: $1,266 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,536.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.91 | 2021-2025 | |
| Pfizer INC. | $589.55 | 2021-2025 | |
| Novo Nordisk INC | $433.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $425.07 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $280.78 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $279.00 | 2022-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $222.68 | 2021-2025 | Repatha, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $171.86 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $164.42 | 2021-2025 | |
| Glaxosmithkline, LLC. | $141.31 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $127.43 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.93 | 2022-2024 | Jardiance |
| Exact Sciences Corporation | $81.57 | 2023-2024 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $80.65 | 2022-2025 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $78.79 | 2023-2025 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $74.66 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $72.62 | 2022-2024 | Myrbetriq, Veozah |
| Merck Sharp & Dohme LLC | $71.84 | 2022-2023 | Verquvo, Belsomra |
| Daiichi Sankyo INC. | $60.64 | 2023-2025 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $54.17 | 2022 | |
| Eisai INC. | $52.43 | 2024-2025 | |
| Esperion Therapeutics, INC. | $46.64 | 2022-2025 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $45.78 | 2021 | |
| Sumitomo Pharma America, INC. | $43.26 | 2024 | Gemtesa |
| Abiomed | $41.37 | 2025 | |
| Ascensia Diabetes Care US INC. | $24.69 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.90 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.66 | 2024 | Keveyis |
| Antares Pharma, INC. | $22.38 | 2022 | |
| Inari Medical, INC. | $20.78 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $18.83 | 2023 | |
| Radius Health, INC. | $18.78 | 2025 | Tymlos |
| Abbott Laboratories | $18.34 | 2021 | |
| Halozyme INC | $13.46 | 2023 | |
| Dynavax Technologies Corporation | $13.10 | 2024 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.